We showed in the PCCL3 cell lines that the MAPK pathway drives the expression of DUSP5 and DUSP6. We hypothesized that DUSP5 and DUSP6 mRNA levels might be a marker for MAPK pathway activation, with differences according to the genetic alteration present in the carcinoma. This evidence concerns the gene DUSP5 and carcinoma.